hunanamycin A: antibiotic from a marine-derived Bacillus hunanensis; structure in first source [MeSH]
| ID Source | ID |
|---|---|
| PubMed CID | 71521235 |
| CHEMBL ID | 5177659 |
| SCHEMBL ID | 16389619 |
| MeSH ID | M0584718 |
| Synonym |
|---|
| hunanamycin a |
| SCHEMBL16389619 |
| CHEMBL5177659 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1908189 | Acute toxicity in Swiss albino mouse assessed as mortality at 2 g/Kg, po administered daily for 14 days | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236ISSN: 1768-3254 | Antibiotic natural product hunanamycin A: Lead identification towards anti-Salmonella agents. |
| AID1908183 | Solubility of compound in DMSO at pH 7.4 after 5 mins measured by HPLC analysis | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236ISSN: 1768-3254 | Antibiotic natural product hunanamycin A: Lead identification towards anti-Salmonella agents. |
| AID1908182 | Solubility of compound in DMSO at pH 4.5 after 5 mins measured by HPLC analysis | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236ISSN: 1768-3254 | Antibiotic natural product hunanamycin A: Lead identification towards anti-Salmonella agents. |
| AID1908185 | Stability in human plasma measured after 60 mins LC-MS/MS analysis | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236ISSN: 1768-3254 | Antibiotic natural product hunanamycin A: Lead identification towards anti-Salmonella agents. |
| AID1853750 | Antibacterial activity against Salmonella enterica ATCC 6539 assessed as bacterial cell growth inhibition measured after 24 hrs by Bactiter-glo assay | 2022 | European journal of medicinal chemistry, Feb-15, Volume: 230ISSN: 1768-3254 | Natural products from mangrove sediments-derived microbes: Structural diversity, bioactivities, biosynthesis, and total synthesis. |
| AID1908181 | Solubility of compound in DMSO at pH 2.2 after 5 mins measured by HPLC analysis | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236ISSN: 1768-3254 | Antibiotic natural product hunanamycin A: Lead identification towards anti-Salmonella agents. |
| AID1908188 | Plasma protein binding in human measured at 150 uM preincubated for 30 mins followed by addition of dialysis buffer measured after 4 hrs by LC-MS/MS analysis | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236ISSN: 1768-3254 | Antibiotic natural product hunanamycin A: Lead identification towards anti-Salmonella agents. |
| AID1908186 | Metabolic stability in mouse liver microsomes measured at 1 uM after 30 mins by LC-MS/MS analysis | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236ISSN: 1768-3254 | Antibiotic natural product hunanamycin A: Lead identification towards anti-Salmonella agents. |
| AID1908179 | Antibacterial activity against Salmonella enterica ATCC 6539 assessed as microbial cell viability incubated for 24 hr by quantification of ATP multimode plate reader method | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236ISSN: 1768-3254 | Antibiotic natural product hunanamycin A: Lead identification towards anti-Salmonella agents. |
| AID1908184 | Solubility of compound in DMSO at pH 10.2 after 5 mins measured by HPLC analysis | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236ISSN: 1768-3254 | Antibiotic natural product hunanamycin A: Lead identification towards anti-Salmonella agents. |
| AID1908180 | Solubility of compound in DMSO at pH 1.2 after 5 mins measured by HPLC analysis | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236ISSN: 1768-3254 | Antibiotic natural product hunanamycin A: Lead identification towards anti-Salmonella agents. |
| AID1908187 | Metabolic stability in human liver microsomes measured at 1 uM after 30 mins by LC-MS/MS analysis | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236ISSN: 1768-3254 | Antibiotic natural product hunanamycin A: Lead identification towards anti-Salmonella agents. |
| AID1908190 | Acute toxicity in Swiss albino mouse assessed as lethal dose administered orally daily for 14 days | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236ISSN: 1768-3254 | Antibiotic natural product hunanamycin A: Lead identification towards anti-Salmonella agents. |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| celecoxib | organofluorine compound; pyrazoles; sulfonamide; toluenes | cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
| elaiophylin | lactol; macrodiolide; monosaccharide derivative | antifungal agent; autophagy inhibitor; bacterial metabolite | 2022 | 2022 | 2.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 | |
| azalomycin-f | 2022 | 2022 | 2.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 | |||
| clasto-lactacystin beta-lactone | 2022 | 2022 | 2.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 | |||
| marizomib | beta-lactone; gamma-lactam; organic heterobicyclic compound; organochlorine compound; salinosporamide | antineoplastic agent; proteasome inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
| aspulvinone E | 4-hydroxy-5-(4-hydroxybenzylidene)-3-(4-hydroxyphenyl)furan-2(5H)-one; aspulvinone | antiviral agent; Aspergillus metabolite; EC 3.2.1.20 (alpha-glucosidase) inhibitor; marine metabolite | 2022 | 2022 | 2.0 | high | 0 | 0 | 0 | 0 | 0 | 1 |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| quinoxalines | mancude organic heterobicyclic parent; naphthyridine; ortho-fused heteroarene | 2013 | 2022 | 7.8 | high | 0 | 0 | 0 | 0 | 3 | 1 | ||
| gold | copper group element atom; elemental gold | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cancer of Liver | 0 | 2017 | 2017 | 7.0 | high | 0 | 0 | 0 | 0 | 1 | 0 | |
| Carcinoma, Hepatocellular | 0 | 2017 | 2017 | 7.0 | high | 0 | 0 | 0 | 0 | 1 | 0 | |
| Hepatocellular Carcinoma | 0 | 2017 | 2017 | 7.0 | high | 0 | 0 | 0 | 0 | 1 | 0 | |
| Liver Neoplasms | 0 | 2017 | 2017 | 7.0 | high | 0 | 0 | 0 | 0 | 1 | 0 |
| Article | Year |
|---|---|
| Antibiotic natural product hunanamycin A: Lead identification towards anti-Salmonella agents. European journal of medicinal chemistry, , Jun-05, Volume: 236 | 2022 |